El número necesario a tratar para la segunda generación de productos biológicos en el tratamiento de la artritis reumatoide establecida: una revisión sistemática cuantitativa de ensayos controlados aleatorios

Categoría Resumen estructurado de revisiones sistemáticas
RevistaDatabase of Abstracts of Reviews of Effects (DARE)
Año 2011
Cargando información sobre las referencias

CRD SUMMARY:

This review concluded that second-generation biological agents were of comparable efficacy with few adverse events in patients with established rheumatoid arthritis taking concomitant methotrexate, but that limited data were available for rituximab, tocilizumab, and golimumab. Absence of a quality assessment of included trials, coupled with over-optimistic interpretation of the review results, indicates that these conclusions should be interpreted with caution.
Epistemonikos ID: 63488b2f2b3e312417a898a837af58961eabd1ff
First added on: Jun 07, 2012